Dabigatran EMA - product-specific guide [Regulatives / Guidelines]

posted by nobody – 2019-02-14 15:01 (794 d 10:36 ago) – Posting: # 19921
Views: 3,086

» » » Aren’t you notoriously shouting “It’s the originator, stupid…”?
» » Could you elaborate on this. No clue what this might mean.
»
» See there.

yeah, but you need irony tags in here,don'T you?

» » If you want a duel, choose your weapon
» » :hungry:
»
» Surströmming?

No chemical weapons.

» » » I’m more concerned about the first footnote in the guidance […]. Was the EMA’s PKWP not aware of the the FDA’s guidance?
» »
» » Narrow therapeutic range... maybe in the USA. In the EU there are no mass tort trials...
»
» I don’t like the idea that someone widens the limits for this stuff.

...maybe we will never see such generics in our lifetime. Wait and see...

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 12 (0 registered, 12 guests [including 3 identified bots]).
Forum time: Monday 02:38 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5